The search for an Alzheimer’s disease cure has been dogged by pharmaceutical failures, but a network of the world’s top dementia scientists released a report saying that the number of drugs making it to phase two and phase three of clinical trials encourages them to believe that a blockbuster may be among compounds in the current development pipeline.
Read the Full Story